SMEs 'carry the hope' in AMR fight, says research network

16 November 2017

The pivotal role that small and medium-sized enterprises (SMEs) play in driving innovation in the antimicrobial resistance (AMR) has been stressed by a new position paper.

Released by the BEAM Alliance (Biotech companies in Europe combating antimicrobial resistance research), which represents 40 members researching in the field, the paper looks at how antibacterial research and development (R&D) could be revived and proposes specific support for SME-driven innovation.

Ensuring adequately-shaped incentive mechanisms that ultimately reward R&D evidence, health technology assessment bodies recognizing the worth of SME innovation, dedicated regulatory pathways and tax incentives are among the proposals put forward.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK